Instalab

Protein Electrophoresis

Spot the protein pattern that flags blood cancer, chronic inflammation, or immune failure before symptoms force the diagnosis.

Who benefits from Protein Electrophoresis testing

Dealing with Unexplained Bone Pain
This panel can reveal protein patterns linked to myeloma, a blood cancer that weakens bones before other tests change.
Getting Sick More Often Than Usual
Low antibody production shows up in the gamma fraction, exposing immune gaps that routine blood work overlooks.
Living with Chronic Liver or Kidney Disease
Your protein pattern shifts in specific ways with organ damage, giving you and your doctor a clearer picture of progression.
Over 50 and Want a Deeper Screen
About 3% of adults over 50 carry an abnormal protein clone that only electrophoresis can detect.

About Protein Electrophoresis

Your blood carries dozens of proteins, each doing a different job. Some fight infection, some carry nutrients, and some keep fluid from leaking out of your blood vessels. When disease disrupts any of these systems, the balance of proteins shifts in characteristic ways. A single total protein number cannot tell you where the shift is happening. Protein electrophoresis can.

This panel separates your blood proteins into distinct groups based on their electrical charge, then measures how much of each group is present. The resulting pattern acts like a fingerprint for your immune system, liver, kidneys, and bone marrow. A sharp spike in one region can signal a blood cancer years before other symptoms appear. A broad rise in another can reveal chronic inflammation or liver scarring. A dip in a third can expose an immune system that has quietly stopped making enough antibodies to protect you.

What This Panel Reveals

The panel divides your blood proteins into five main zones. The largest fraction, albumin, is made by the liver and keeps fluid inside your blood vessels while ferrying hormones and medications through the body. When albumin drops, it usually points to liver disease, kidney protein loss, malnutrition, or chronic inflammation.

The alpha fractions (alpha-1 and alpha-2 globulins) are acute phase proteins, meaning they rise when the body is fighting infection, inflammation, or tissue damage. Alpha-1 antitrypsin, the main component of the alpha-1 band, protects lungs from enzyme damage. The alpha-2 band includes haptoglobin (a protein that mops up free hemoglobin from damaged red blood cells) and alpha-2 macroglobulin (a large protein that rises dramatically when the kidneys leak protein).

The beta zone contains transferrin (the body's main iron transporter), complement proteins (part of the immune defense system), and some immunoglobulins (antibodies). The beta region is often split into two sub-fractions. Changes here can reflect iron deficiency, immune activation, or early signs of an abnormal protein.

The gamma zone is where the panel earns its keep. This region contains your immunoglobulins, the antibodies your immune system makes to fight specific threats. A normal gamma region looks like a broad, gentle hill. A narrow spike in this region, called an M-spike (monoclonal spike), means one clone of immune cells is producing a single type of antibody in excess. That pattern is the hallmark of conditions ranging from a common, often harmless precursor state to outright blood cancer.

The M-Spike: Why One Sharp Peak Matters

The single most important finding on protein electrophoresis is the M-spike. In a study of 21,463 residents of Olmsted County, Minnesota, 3.2% of people over age 50 had a monoclonal protein detected on screening. That condition, called monoclonal gammopathy of undetermined significance (MGUS), progresses to a serious blood disorder such as multiple myeloma, lymphoma, or amyloidosis (a condition where abnormal proteins build up in organs) at a rate of about 1% per year. The risk never goes away, even decades later.

Multiple myeloma, the most common cancer of the antibody-producing immune cells, affects roughly 35,000 Americans each year. It often announces itself through bone pain, kidney failure, anemia, or recurrent infections. But the M-spike on electrophoresis can appear years before any of those problems develop. Detecting it early changes the monitoring and treatment timeline entirely.

Not every M-spike means cancer. Most people with MGUS will never progress. But without the electrophoresis pattern, you would not know MGUS exists in the first place, and you would not know to watch for progression.

How to Read Your Results Together

No single fraction on this panel tells the full story. The power is in reading the pattern across all zones simultaneously. The table below shows the most common patterns and what they suggest.

PatternWhat It SuggestsTypical Next Step
Sharp spike in gamma region (M-spike) with otherwise normal fractionsMonoclonal gammopathy: could be MGUS, smoldering myeloma, or active myelomaImmunofixation electrophoresis and serum free light chains to identify the protein type
Broad elevation across the entire gamma region (polyclonal gammopathy)Chronic infection, autoimmune disease, or liver disease such as cirrhosisLiver function tests, hepatitis panel, autoimmune workup depending on clinical picture
Low gamma region with normal or near-normal other fractionsImmunodeficiency: the body is not producing enough antibodiesQuantitative immunoglobulins (IgG, IgA, IgM) to identify which antibody class is low
High alpha-2 with low albuminNephrotic syndrome: kidneys are leaking protein into the urineUrine albumin to creatinine ratio and kidney function panel

A few subtler patterns deserve attention. When albumin is low and gamma globulins are high, the combination often points to chronic liver disease, because a damaged liver makes less albumin while a chronically stimulated immune system floods the gamma zone. When alpha-1 globulins are unusually low, it may signal alpha-1 antitrypsin deficiency, a genetic condition that raises the risk of early lung disease and liver damage.

When Results Can Be Misleading

Acute illness can temporarily reshape the entire electrophoresis pattern. A severe infection or recent surgery can raise alpha-1 and alpha-2 fractions while dropping albumin, mimicking a disease pattern that disappears once you recover. Dehydration can concentrate all fractions upward, making values look falsely high. Overhydration does the opposite.

Some medications, including certain antibiotics and anticonvulsants (seizure medications), can produce a band that looks like a small M-spike but is actually a drug artifact. If you are taking any medications when this panel is drawn, note them so results can be interpreted correctly. Pregnancy also shifts the pattern, typically raising alpha-2 globulins and lowering albumin.

Protein electrophoresis alone cannot diagnose multiple myeloma. An M-spike triggers a workup, not a diagnosis. Immunofixation electrophoresis (a more detailed test that identifies the exact antibody type) and free light chain testing are typically the next steps. Light chains are small antibody fragments, and about 15% to 20% of myeloma cases produce only light chains without forming a visible M-spike, which is why free light chain testing is an important companion to standard electrophoresis.

Tracking Over Time

A single electrophoresis result is a snapshot. Serial results reveal a trajectory. For anyone with MGUS, guidelines from the International Myeloma Working Group recommend periodic monitoring to catch progression early. A stable M-spike that has not grown over several years carries lower risk than one that is steadily climbing.

Even without an M-spike, tracking your protein pattern over time reveals shifts in immune function, nutritional status, and inflammatory burden that a single draw cannot capture. A gradually declining albumin, for example, may signal worsening liver function or chronic protein loss long before other tests change. A slowly rising gamma fraction may be the first sign of a brewing autoimmune condition.

Frequently Asked Questions

References

6 studies
  1. O'connell TX, Horita TJ, Kasravi BAmerican Family Physician2005
  2. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri a, Katzmann JA, Melton LJ 3RdNew England Journal of Medicine2006
  3. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3RdNew England Journal of Medicine2002
  4. Rajkumar SV, Dimopoulos MA, Palumbo a, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri a, Weiss B, Leleu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JFLancet Oncology2014
  5. Tate JRClinical Biochemist Reviews2019